Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | President | November 19, 2022 | November 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date November 19, 2022 · Filed November 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,234 |
Ending reported balance
After 2022-11-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-11-19 · Exercise / conversion · Acquired 6,250 · Balance 63,081 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2022-11-21 · Sale · Disposed 1,847 · Balance 61,234 F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-21 · Exercise / conversion · Disposed 6,250 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The restricted stock units vest in four equal annual installments beginning November 19, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: The restricted stock units vest in four equal annual installments beginning November 19, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2020 Filed Nov 21, 2020 02:29 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,728 | $53.50 | $145,948.00 |
DisclosureSEC source: 0001209191-20-059854 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,528 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 02:29 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059854 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 11/19/2019. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 11/19/2019. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 02:29 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059854 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 16, 2020 Filed Oct 19, 2020 21:26 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,297 | $42.56 | $55,200.32 |
DisclosureSEC source: 0001209191-20-055316 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,006 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:26 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055316 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,938 Underlying: Common Stock · 2,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:26 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055316 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 19, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,452 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · derivative · entry 10 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 16,452 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on November 19, 2019. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| June 19, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 16,452 | $50.12 | $824,515.01 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · nonDerivative · entry 6 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,334 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2019. F3 · price: were sold in multiple transactions at prices ranging from $50.00 to $50.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 19, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 16,452 | $18.12 | $298,110.24 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · nonDerivative · entry 5 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 39,798 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · derivative · entry 9 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,202 Underlying: Common Stock · 39,798 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on November 19, 2019. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 17,494 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · derivative · entry 8 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,112 Underlying: Common Stock · 17,494 shares Expires 2028-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,551 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · derivative · entry 7 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,551 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 65,843 | $50.01 | $3,292,729.42 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · nonDerivative · entry 4 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,334 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.175, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 39,798 | $18.12 | $721,139.76 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · nonDerivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 17,494 | $19.98 | $349,530.12 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 22:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,551 | $19.65 | $168,027.15 |
DisclosureSEC source: 0001209191-20-038065 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 4,308 | $49.21 | $211,996.68 |
DisclosureSEC source: 0001209191-20-026614 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,334 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| April 29, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026614 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,847 Underlying: Common Stock · 9,615 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. Read SEC document |
| April 29, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-026614 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,875 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0001209191-20-025677 · doc4.xml · derivative · entry 5 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,625 Underlying: Common Stock · 11,875 shares Expires 2028-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,074 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-20-025677 · doc4.xml · derivative · entry 4 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,551 Underlying: Common Stock · 7,074 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 18,949 | $50.07 | $948,729.06 |
DisclosureSEC source: 0001209191-20-025677 · doc4.xml · nonDerivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 11,875 | $21.28 | $252,700.00 |
DisclosureSEC source: 0001209191-20-025677 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 7,074 | $19.65 | $139,004.10 |
DisclosureSEC source: 0001209191-20-025677 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2020 Filed Apr 22, 2020 22:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 19,644 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001209191-20-025379 · doc4.xml · derivative · entry 8 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,606 Underlying: Common Stock · 19,644 shares Expires 2028-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| April 22, 2020 Filed Apr 22, 2020 22:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 34,375 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-20-025379 · doc4.xml · derivative · entry 7 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 34,375 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 22, 2020 Filed Apr 22, 2020 22:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 54,019 | $50.02 | $2,701,906.14 |
DisclosureSEC source: 0001209191-20-025379 · doc4.xml · nonDerivative · entry 5 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 22, 2020 Filed Apr 22, 2020 22:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 19,644 | $19.98 | $392,487.12 |
DisclosureSEC source: 0001209191-20-025379 · doc4.xml · nonDerivative · entry 4 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2020 Filed Apr 22, 2020 22:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 34,375 | $19.65 | $675,468.75 |
DisclosureSEC source: 0001209191-20-025379 · doc4.xml · nonDerivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 22:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-20-025379 · doc4.xml · derivative · entry 6 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 100,000 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 22:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 100,000 | $50.15 | $5,015,450.00 |
DisclosureSEC source: 0001209191-20-025379 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 22:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 100,000 | $19.65 | $1,965,000.00 |
DisclosureSEC source: 0001209191-20-025379 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 21,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002598 · doc4.xml · derivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,777 Underlying: Common Stock · 21,777 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 79,031 | $0.00 Strike: $42.81 | $0.00 |
DisclosureSEC source: 0001209191-20-002598 · doc4.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,031 Underlying: Common Stock · 79,031 shares Expires 2030-01-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 6, 2021. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 22:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-057636 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 11/19/2019. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 11/19/2019. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 22:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,160 | $46.41 | $100,245.60 |
DisclosureSEC source: 0001209191-19-057636 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,027 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price, and includes 2,153 shares sold at $46.41 and 7 shares sold at $46.7644. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 22:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-057636 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053492 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,907 Underlying: Common Stock · 2,968 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,031 | $39.65 | $40,879.15 |
DisclosureSEC source: 0001209191-19-053492 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,937 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,968 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053492 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 29, 2019 Filed May 1, 2019 21:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 38,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026844 · doc4.xml · derivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,462 Underlying: Common Stock · 38,462 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2019 Filed May 1, 2019 21:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 134,953 | $0.00 Strike: $25.12 | $0.00 |
DisclosureSEC source: 0001209191-19-026844 · doc4.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,953 Underlying: Common Stock · 134,953 shares Expires 2029-04-29 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-059445 · doc4.xml · derivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning November 19, 2019. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning November 19, 2019. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 21:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantEmployee Stock Options (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001209191-18-059445 · doc4.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-11-18 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on November 19, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 15, 2018 Filed Oct 24, 2018 20:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 11,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-027360 · doc4.xml · derivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 Underlying: Common Stock · 11,875 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning October 15, 2019. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning October 15, 2019. Read SEC document |
| October 15, 2018 Filed Oct 24, 2018 20:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 47,500 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0000899243-18-027360 · doc4.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2028-10-15 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on October 15, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 22:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 71,250 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-18-000656 · form4-04202018_030430.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,250 Underlying: Common Stock · 71,250 shares Expires 2028-04-17 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 22:13 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001470 · form4-09082017_030927.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 93,750 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000408 · form4-03102017_050352.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.